Breadcrumb

Breadcrumbs

Press Releases

Search Results

Back to Press Releases
Showing 21 - 30 of 35 results.

You searched for : August 2019 to August 2020.

Phase 2 DESTINY-Gastric01 Trial of DS-8201 Versus Chemotherapy Met Primary Endpoint

Phase 2 DESTINY-Gastric01 Trial of DS-8201 Versus Chemotherapy Met Primary Endpoint Download the PDF version of Article January 27, 2020 Trial met primary endpoint of objective response rate and...

ENHERTU® Now Available in U.S. for HER2 Positive Unresectable or Metastatic Breast Cancer Following ...

ENHERTU® Now Available in U.S. for HER2 Positive Unresectable or Metastatic Breast Cancer Following Two or More Prior Anti-HER2-Based Regimens Download the PDF version of Article January 06, 2020...

ENHERTU® Approved in the U.S. for HER2 Positive Unresectable or Metastatic Breast Cancer Following ...

ENHERTU® Approved in the U.S. for HER2 Positive Unresectable or Metastatic Breast Cancer Following Two or More Prior Anti-HER2-Based Regimens Download the PDF version of Article December 20, 2019...

DS-8201 ([Fam-] Trastuzumab Deruxtecan) Achieved A Tumor Response Rate of 60.9% in Pivotal Phase 2 ...

DS-8201 ([Fam-] Trastuzumab Deruxtecan) Achieved A Tumor Response Rate of 60.9% in Pivotal Phase 2 HER2 Positive Metastatic Breast Cancer Trial Download the PDF version of Article December 11, 2019...

Positive Pivotal Data for Daiichi Sankyo’s DS-8201 ([Fam]-Trastuzumab Deruxtecan) in Patients with ...

Positive Pivotal Data for Daiichi Sankyo’s DS-8201 ([Fam]-Trastuzumab Deruxtecan) in Patients with HER2 Positive Metastatic Breast Cancer to be Presented at SABCS Download the PDF version of...

Daiichi Sankyo Data at ASH Showcases Scientific and Clinical Advancements Across AML/Blood Cancer P ...

Daiichi Sankyo Data at ASH Showcases Scientific and Clinical Advancements Across AML/Blood Cancer Portfolio Download the PDF version of Article November 06, 2019 Three oral presentations to feature...

Daiichi Sankyo Files Declaratory Judgement Action Related to its Proprietary Antibody Drug Conjugat ...

Daiichi Sankyo Files Declaratory Judgement Action Related to its Proprietary Antibody Drug Conjugate Technology Download the PDF version of Article November 04, 2019 Tokyo, Japan, Munich, Germany,...

Daiichi Sankyo Initiates Clinical Trial with its 4th DXd Antibody Drug Conjugate, DS-7300, in Colla ...

Daiichi Sankyo Initiates Clinical Trial with its 4th DXd Antibody Drug Conjugate, DS-7300, in Collaboration with Sarah Cannon Research Institute Download the PDF version of Article October 31, 2019...

[Fam-] Trastuzumab Deruxtecan (DS-8201) Granted FDA Priority Review for Treatment of Patients with ...

[Fam-] Trastuzumab Deruxtecan (DS-8201) Granted FDA Priority Review for Treatment of Patients with HER2 Positive Metastatic Breast Cancer Download the PDF version of Article October 17, 2019 Tokyo,...

Updated Clinical Results and New Biomarker Analyses Presented for Daiichi Sankyo’s DS-1062 in Patie ...

Updated Clinical Results and New Biomarker Analyses Presented for Daiichi Sankyo’s DS-1062 in Patients with Advanced NSCLC at 2019 World Conference on Lung Cancer Download the PDF version of...

Press Release More Stories

More Stories

Who We Are

As the U.S. subsidiary of a global pharmaceutical innovator, Daiichi Sankyo, Inc. draws on a rich heritage of innovation, integrity and accountability..

read more ...